FDA.reportPublic FDA data

netupitant 300 MG / palonosetron 0.5 MG Oral Capsule

RxCUI
1552343
RxNorm name
netupitant 300 MG / palonosetron 0.5 MG Oral Capsule
Display name
netupitant 300 MG / palonosetron 0.5 MG Oral Capsule
Full name
netupitant 300 MG / palonosetron 0.5 MG Oral Capsule
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:08

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
AKYNZEONETUPITANT AND PALONOSETRONHelsinn Therapeutics (U.S.), Inc.8e47618e-af46-4d82-94e8-1507c042252d2026-06-23Warnings, Adverse reactionsExact identifier
rxcui: 1552343

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
8e47618e-af46-4d82-94e8-1507c042252dnetupitant 300 MG / palonosetron 0.5 MG Oral Capsule [PSN] · netupitant 300 MG / palonosetron 0.5 MG Oral Capsule [SCD] · netupitant 300 MG / palonosetron 0.5 MG (as palonosetron hydrochloride 0.56 MG) Oral Capsule [SY]318These highlights do not include all the information needed to use AKYNZEO® safely and effectively. See full prescribing information for AKYNZEO®. AKYNZEO® (netupitant and palonosetron) capsules, for oral use Initial U.S. Approval: 2014 AKYNZEO® (fosnetupitant and palonosetron) for injection, for intravenous use Initial U.S. Approval: 201820260126